5 years ago
1
Big pharma can only see the benefit of R&D for wealthy markets
There is too little incentive for pharmaceutical companies to work on treatments for diseases of low-income countries
Continue Reading https://www.theguardian.com
Join the Discussion
Yep,if they can't line their pockets really fast they won't bother,just let um die.